After securing a new $26 million investment round, Molecular Assemblies announced the intent to provide commercial access to the company’s Fully Enzymatic Synthesis (FES)™ technology via a Key Customer Program. Many fields rely on synthetic DNA, including vaccine production and precision gene editing, and the company’s FES™ technology can overcome the immense bottleneck of the current chemical DNA synthesis method.
“The ability to generate long, pure, accurate DNA with our FES technology can accelerate many applications, such as CRISPR, next generation sequencing, and the assembly of genes for numerous synthetic biology applications.” – Michael Kamdar, President and CEO of Molecular Assemblies
